Motor neurone disease: assessment and management

Excerpt

This guideline covers assessing and managing motor neurone disease (MND). It aims to improve care from the time of diagnosis, and covers information and support, organisation of care, managing symptoms and preparing for end of life care.

MHRA advice on gabapentin: In July 2019 we added a footnote to this guideline to reflect a change in the law relating to gabapentin. As of 1 April 2019, because of a risk of abuse and dependence gabapentin is controlled under the Misuse of Drugs Act 1971 as a class C substance and is scheduled under the Misuse of Drugs Regulations 2001 as schedule 3.

Who is it for?:

1. Healthcare professionals and social care practitioners caring for and supporting adults with MND

2. Commissioners and providers of MND health and social care services

3. Adults with MND, their families and carers